Enliven therapeutics announces details regarding the presentation of updated elvn-001 phase 1a data at the esh-icmlf 26th annual john goldman conference on cml

Boulder, colo., sept. 18, 2024 (globe newswire) -- enliven therapeutics, inc. (enliven or the company) (nasdaq: elvn), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated elvn-001 phase 1a data, which was selected for an oral presentation at the upcoming european society of hematology international chronic myeloid leukemia foundation (esh-icmlf) 26th annual john goldman conference taking place september 27-29 in prague, czech republic.
ELVN Ratings Summary
ELVN Quant Ranking